Affiliation
Molecular Oncology Group, The Paterson Institute for Cancer Research, The University of Manchester, Manchester, United Kingdom.Issue Date
2013-05
Metadata
Show full item recordAbstract
Summary: The promise of personalized medicine is upon us, and in some cancers, targeted therapies are rapidly becoming the mainstay of treatment for selected patients based on their molecular profile. The protein kinase BRAF is a driver oncogene in both thyroid cancer and melanoma, but while drugs that target BRAF and its downstream signaling pathway are effective in melanoma, they are ineffective in thyroid cancer. In this issue of Cancer Discovery, Montero-Conde and colleagues investigate why thyroid cancer is resistant to BRAF inhibitors despite the presence of BRAF mutation. Cancer Discov; 3(5); 487-90. ©2013 AACR.Citation
Deja Vu: EGF Receptors Drive Resistance to BRAF Inhibitors. 2013, 3 (5):487-90 Cancer DiscovJournal
Cancer DiscoveryDOI
10.1158/2159-8290.CD-13-0131PubMed ID
23658295Type
ArticleLanguage
enISSN
2159-8290ae974a485f413a2113503eed53cd6c53
10.1158/2159-8290.CD-13-0131
Scopus Count
Collections
Related articles
- Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
- Authors: Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, Zambon A, Sinclair J, Hayes A, Gore M, Lorigan P, Springer C, Larkin J, Jorgensen C, Marais R
- Issue date: 2013 Feb
- BRAF as a therapeutic target: a patent review (2006 - 2012).
- Authors: Zambon A, Niculescu-Duvaz D, Niculescu-Duvaz I, Marais R, Springer CJ
- Issue date: 2013 Feb
- BRAF inhibitors in cancer therapy.
- Authors: Hertzman Johansson C, Egyhazi Brage S
- Issue date: 2014 May
- Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.
- Authors: Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, Ryder M, Ghossein RA, Rosen N, Fagin JA
- Issue date: 2013 May
- Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
- Authors: Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J
- Issue date: 2008 Jun 15